• Anjali Maurya
• Dr. Narendra Pratap Singh Sengar

Quinazoline derivatives are heterocyclic compounds with significant therapeutic potential, especially as dipeptidyl peptidase-4 (DPP-4) inhibitors, a target for managing Type 2 Diabetes Mellitus (T2DM). This study reports the synthesis of novel quinazoline derivatives through a three-step process involving benzoxazinone precursors and Schiff base formation. The compounds were characterized using infrared (IR) spectroscopy, nuclear magnetic resonance (NMR), and mass spectrometry. Molecular docking studies were performed using AutoDock Vina to evaluate their potential as DPP-4 inhibitors, comparing the binding affinities and interactions of the synthesized compounds with those of sitagliptin, a known DPP-4 inhibitor. Docking results demonstrated favorable binding affinities, with some compounds showing interactions comparable to sitagliptin. These findings indicate that quinazoline derivatives hold promise as therapeutic agents for the treatment of T2DM.

quinazoline, heterocyclic compounds, DPP-4 inhibitors, Type 2 Diabetes Mellitus, molecular docking, sitagliptin

"Synthesis and Molecular Docking of Quinazoline Derivatives as Potential DPP-4 Inhibitors for Type 2 Diabetes Mellitus", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 12, page no.f143-f148, December-2024, Available :http://www.jetir.org/papers/JETIR2412518.pdf

"Synthesis and Molecular Docking of Quinazoline Derivatives as Potential DPP-4 Inhibitors for Type 2 Diabetes Mellitus", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 12, page no. ppf143-f148, December-2024, Available at : http://www.jetir.org/papers/JETIR2412518.pdf